Reportlinker Adds U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
NEW YORK, May 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
This research service covers the U.S. rheumatoid arthritis (RA) market from 2007 to 2017, with 2010 as the base year. Included in this research service are products currently in the market, products in development, and patient forecasts. Market challenges, drivers, and restraints are identified and assessed. Strategic recommendations are presented to overcome listed industry challenges. This research service does not include market revenue forecasts for DMARDs. This research service highlights product forecasts for biologic products as well as small molecules near launch.
Table of Contents
Scope
10
Methodology
Methodology
11
Market Introduction
RA Background
13
Epidemiology
14
Risk Factors
15
Diagnosis
16
Treatment Paradigm
17
Patient Outlook
Patient Forecast of RA in the United States
19
RA Patients Requiring Add-on Therapy, Forecast in the United States
20
Patients Taking Add-on Therapy Forecast in the United States
21
Industry Challenges
23
Current Treatments
28
Key Trends
31
Market Drivers and Restraints
33
Market Drivers
34
Market Analysis and Forecasts
Market Engineering Measurements
41
Revenue Forecastsfor Biologics and New Treatments
42
Product Forecasts
Forecasting Assumptions
44
Enbrel: Revenue Forecasts
45
Humira: Revenue Forecasts
46
Remicade: Revenue Forecasts
47
Cimzia: Revenue Forecasts
48
Simponi: Revenue Forecasts
49
Rituxan: Revenue Forecasts
50
Orencia: Revenue Forecasts
51
Actemra: Revenue Forecasts
52
CP-690,550: Revenue Forecasts
53
FostamatinibDisodium: Revenue Forecasts
54
Competitive Analysis
Rheumatoid Arthritis Market: Competitive Structure
56
Rheumatoid Arthritis Market: Revenue Market Share Analysis
57
Pipeline Analysis
RA Competitive Landscape
59
Late-stage RA Compounds: Clinical Trial Overview
60
U.S. Small Molecule Approval Timeline
62
Strategic Recommendations
Strategic Recommendations
64
Conclusions
67
About Frost & Sullivan
Who is Frost & Sullivan
69
What Makes Us Unique
70
T.E.A.M. Methodology
71
Global Perspective
72
List of Figures
Rheumatoid Arthritis Market: Patient Forecast (U.S.), 2007-2017
19
Rheumatoid Arthritis Market: Patient Requiring Add-on Therapy Forecast (U.S.), 2007-2017
20
Rheumatoid Arthritis Market: Total RA Anti-TNF Population Forecast (U.S.), 2007-2017
21
Rheumatoid Arthritis Market: Impact of Industry Challenges (U.S.), 2011-2017
23
Rheumatoid Arthritis Market: Current Treatments (U.S.), 2010
28
Rheumatoid Arthritis Market: Current Biologic Therapies (U.S.), 2010
29
Rheumatoid Arthritis Market: Market Drivers Ranked in the Order of Impact (U.S.), 2011-2017
34
Rheumatoid Arthritis Market: Market Restraints Ranked in the Order of Impact (U.S.), 2011-2017
37
Rheumatoid Arthritis Market : Revenue Forecasts for Biologics and New Treatments (U.S.), 2010
42
Rheumatoid Arthritis Market: Forecasting Assumptions (U.S.), 2010
44
Rheumatoid Arthritis Market: Revenue Forecasts for Enbrel(U.S.), 2007-2017
45
Rheumatoid Arthritis Market: Revenue Forecasts for Humira(U.S.), 2007-2017
46
Rheumatoid Arthritis Market: Revenue Forecasts for Remicade(U.S.), 2007-2017
47
Rheumatoid Arthritis Market: Revenue Forecasts for Cimzia(U.S.), 2007-2017
48
Rheumatoid Arthritis Market: Revenue Forecasts for Simponi(U.S.), 2007-2017
49
Rheumatoid Arthritis Market: Revenue Forecasts for Rituxan(U.S.), 2007-2017
50
Rheumatoid Arthritis Market: Revenue Forecasts for Orencia(U.S.), 2007-2017
51
Rheumatoid Arthritis Market: Revenue Forecasts for Actemra(U.S.), 2007-2017
52
Rheumatoid Arthritis Market: Revenue Forecasts for CP-690,550 (U.S.), 2007-2017
53
Rheumatoid Arthritis Market: Revenue Forecasts for FostamatinibDisodium (U.S.), 2007-2017
54
Rheumatoid Arthritis Market: Competitive Structure for Biologics and New Treatments (U.S.), 2010
56
Rheumatoid Arthritis Market : Market Share Analysis for Biologics(U.S.), 2010
57
Rheumatoid Arthritis Market: Clinical Trial Overview (U.S.), 2010
60
List of Charts
Rheumatoid Arthritis Market: Treatment Paradigm (U.S.), 2010
17
Rheumatoid Arthritis Market: Market Drivers and Restraints (U.S.), 2011-2017
33
Rheumatoid Arthritis Market: Market Engineering MeasurementsforBiologics and New Treatments (U.S.), 2010
41
Rheumatoid Arthritis Market: Revenue Forecasts for Biologics and New Treatments (U.S.), 2007-2017
42
Rheumatoid Arthritis Market: Revenue Forecasts for Enbrel(U.S.), 2007-2017
45
Rheumatoid Arthritis Market: Revenue Forecasts for Humira(U.S.), 2007-2017
46
Rheumatoid Arthritis Market: Revenue Forecasts for Remicade(U.S.), 2007-2017
47
Rheumatoid Arthritis Market: Revenue Forecasts for Cimzia(U.S.), 2007-2017
48
Rheumatoid Arthritis Market: Revenue Forecasts for Simponi(U.S.), 2007-2017
49
Rheumatoid Arthritis Market: Revenue Forecasts for Rituxan(U.S.), 2007-2017
50
Rheumatoid Arthritis Market: Revenue Forecasts for Orencia(U.S.), 2007-2017
51
Rheumatoid Arthritis Market: Revenue Forecasts for Actemra(U.S.), 2007-2017
52
Rheumatoid Arthritis Market: Revenue Forecasts for CP-690,550 (U.S.), 2007-2017
53
Rheumatoid Arthritis Market: Revenue Forecasts for FostamatinibDisodium (U.S.), 2007-2017
54
Rheumatoid Arthritis Market: Market Share Analysis for Biologics (U.S.), 2010
57
Rheumatoid Arthritis Market: Competitive Landscape (U.S.), 2010
59
Rheumatoid Arthritis Market: Small Molecule Approval Timeline (U.S.), 2011-2017
62
Rheumatoid Arthritis Market: Key Stakeholders (U.S.), 2010
64
To order this report:
: U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article